Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products

References

• Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901–903. doi: 10.1210/jcem-18-8-901
   PubMed Web of Science ®Google Scholar
• Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child. 1979;54(8):609–613. doi: 10.1136/adc.54.8.609
   PubMed Web of Science ®Google Scholar
• Laursen T, Gravholt CH, Heickendorff L, et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor System, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-Deficient adults. J Clin Endocrinol Metab. 2022;86(3):1222–8. doi: 10.1210/jc.86.3.1222
   Google Scholar
• August GP, Julius JR, Blethen SL. Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National cooperative growth study experience. Pediatrics. 1998;102(Supplement_3):512–6. doi: 10.1542/peds.102.S3.512
   PubMedGoogle Scholar
• Bell JJ, Lippe B, Romano AA, et al. National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries. Pediatr Endocrinol Rev. 2018;16(2):240–255. doi: 10.17458/per.vol16.2018.25yearsghdata
   PubMed Web of Science ®Google Scholar
• Child CJ, Zimmermann AG, Chrousos GP, et al. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab. 2019;104(2):379–9. doi: 10.1210/jc.2018-01189
   PubMed Web of Science ®Google Scholar
• Pfaffle R, Bidlingmaier M, Kreitschmann-Andermahr I, et al. Safety and effectiveness of Omnitrope®, a biosimilar recombinant human growth hormone: more than 10 years’ experience from the PATRO children study. Horm Res Paediatr. 2020;93(3):154–163. doi: 10.1159/000508190
   PubMed Web of Science ®Google Scholar
• Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. 2006;91(6):2047–2054. doi: 10.1210/jc.2005-2284
   PubMed Web of Science ®Google Scholar
• Ross JL, Lee PA, Gut R, et al. Attaining genetic height potential: analysis of height outcomes from the ANSWER program in children treated with growth hormone over 5 years. Growth Horm IGF Res. 2015;25(6):286–93. doi: 10.1016/j.ghir.2015.08.006
   PubMed Web of Science ®Google Scholar
• Miller BS, Rose SR, Ross JL, et al. Growth hormone dosage associated with change in height standard deviation score over 4 years of treatment by age in pediatric patients with isolated growth hormone deficiency (IGHD): results from the ANSWER program. Growth II Posters. Pediatric Academic Societies’ Meeting; San Diego, CA. p. 1519.142; 2015.
   Google Scholar
• Aguiar-Oliveira MH, Meneguz-Moreno RA, Nascimento-Junior AC. Novas opções e preparações na terapia com hormônio de crescimento. Arq Bras Endocrinol Metabol. 2008;52(5):917–24. doi: 10.1590/S0004-27302008000500024
   PubMedGoogle Scholar
• Auer MK, Stieg MR, Hoffmann J, et al. Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? Clin Endocrinol. 2016;84(6):862–869. doi: 10.1111/cen.13030
   PubMed Web of Science ®Google Scholar
• Mancini A, Vergani E, Bruno C, et al. Relevance of adherence monitoring in adult patients with growth hormone deficiency under replacement therapy: preliminary monocentric data with easypod TM connect. Front Endocrinol. 2019;10:416. doi: 10.3389/fendo.2019.00416
   PubMed Web of Science ®Google Scholar
• Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1–8. doi: 10.1530/EJE-16-0111
   PubMed Web of Science ®Google Scholar
• Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - Current status and future considerations. J Clin Endocrinol Metab. 2020;105(6):e2121–33. doi: 10.1210/clinem/dgz149
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A research study in children born small and who stayed small. Treatment is somapacitan Once a week compared to Norditropin® Once a Day 2019 [updated 2022 Feb 24]. Accessed 2023 Apr 22. Available from: https://clinicaltrials.gov/ct2/show/NCT03878446
   Google Scholar
• Miller BS, Blair JC, Rasmussen MH, et al. Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized Phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107(12):3378–3388. doi: 10.1210/clinem/dgac513
   PubMed Web of Science ®Google Scholar
• Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the Phase 3 heiGht trial. J Clin Endocrinol Metab. 2021;106(11):3184–95. doi: 10.1210/clinem/dgab529
   PubMed Web of Science ®Google Scholar
• Thornton PS, Nadgir UM, Hofman P, et al. Safety and efficacy of treatment with lonapegsomatropin in children with growth hormone deficiency at week 130 in the enliGhten trial. Atlanta (GA) USA: ENDO; 2022.
   Google Scholar
• Ascendis. SKYTROFA™ (lonapegsomatropin-tcgd) for injection, for subcutaneous use (2021) [Updated 2022 Feb 12]. Accessed 2023 Apr 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf
   Google Scholar
• Zelinska N, Iotova V, Skorodok J, et al. Long-acting C-Terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102(5):1578–1587. doi: 10.1210/jc.2016-3547
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Assessment Report: Ngenla. (2021) [cited 2022 Sep 4]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ngenla-epar-public-assessment-report_en.pdf
   Google Scholar
• Deal CL, Pastrak A, Silverman LA, et al. OR10-06 somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric Phase 3 clinical trial. J Endocr Soc. 2020;4(Supplement_1):OR10–06. doi: 10.1210/jendso/bvaa046.1279
   Google Scholar
• Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a Phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717–28. doi: 10.1210/clinem/dgac220
   PubMed Web of Science ®Google Scholar
• Wajnrajch M, Miller BS, Steelman J, et al. Switch data from the open-label extension of the pivotal phase 3 study of Once weekly somatrogon compared to daily somatropin in pediatric patients with growth hormone deficiency (pGHD). J Endocr Soc. 2021;5(Supplement_1):A686–7. doi: 10.1210/jendso/bvab048.1399
   Google Scholar
• Pfizer Canada, ULC. NGENLA (Somatrogon). 2021. Accessed 2022 Oct 7. Available from: https://www.pfizer.ca/sites/default/files/202111/NGENLA_PM_EN_246729_26-Oct-2021.pdf
   Google Scholar
• Fares FA, Havron A, Fima E. Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin β subunit to the N-Terminal and C-Terminal coding sequence. Int J Cell Biol. 2011;2011:1–7. doi: 10.1155/2011/275063
   Google Scholar
• Fares FA, Suganuma N, Nishimori K, et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Nat Acad Sci U S A. 1992;89(10):4304–4308. doi: 10.1073/pnas.89.10.4304
   PubMed Web of Science ®Google Scholar
• Hershkovitz O, Bar-Ilan A, Guy R, et al. In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm. 2016;13(2):631–9. doi: 10.1021/acs.molpharmaceut.5b00868
   PubMedGoogle Scholar
• Bar-Ilan A, Livnat T, Hoffman M, et al. In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. Haemophilia. 2018;24(3):477–486. doi: 10.1111/hae.13428
   PubMed Web of Science ®Google Scholar
• Strasburger CJ, Vanuga P, Payer J, et al. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. 2017;176(3):283–294. doi: 10.1530/EJE-16-0748
   PubMed Web of Science ®Google Scholar
• Fisher DM, Rosenfeld RG, Jaron-Mendelson M, et al. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr. 2017;87(5):324–332. doi: 10.1159/000470842
   PubMed Web of Science ®Google Scholar
• Lin Z, Shu AD, Bach M, et al. Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency. J Endocr Soc. 2022;6(1):bvab168. doi: 10.1210/jendso/bvab168
   PubMed Web of Science ®Google Scholar
• Varewijck AJ, Lamberts SWJ, van der Lely AJ, et al. The Introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. J Clin Endocrinol Metab. 2015;100(1):309–16. doi: 10.1210/jc.2014-2558
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Schilbach K. The use of IGF-I to monitor long-acting growth hormone therapy-timing is an art. J Clin Endocrinol Metab. 2021;106(5):e2367–9. doi: 10.1210/clinem/dgab016
   PubMed Web of Science ®Google Scholar
• Kramer WG, Jaron-Mendelson M, Koren R, et al. Pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and caucasian adults. Clin Pharmacol Drug Dev. 2018;7(5):554–63. doi: 10.1002/cpdd.414
   PubMed Web of Science ®Google Scholar
• Savendahl L, Battelino T, Brod M, et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab. 2020;105(4):e1847–61. doi: 10.1210/clinem/dgz310
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Carakushansky M, Galcheva S, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6(10):bvac117. doi: 10.1210/jendso/bvac117
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase 3, multicenter study to evaluate the efficacy and safety of MOD-4023 in adults with growth hormone deficiency. (2022) Accessed 2023 Apr 22. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01909479
   Google Scholar
• Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480–2486. doi: 10.1210/jc.2007-0204
   PubMed Web of Science ®Google Scholar
• Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1–P9. doi: 10.1530/EJE-15-0873
   PubMed Web of Science ®Google Scholar
• Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res Paediatr. 2004;62(Suppl 1):59–65. doi: 10.1159/000080760
   Google Scholar
• Lamb YN. Somatrogon: first approval. Drugs. 2022;82(2):227–234. doi: 10.1007/s40265-021-01663-2
   PubMed Web of Science ®Google Scholar
• Business Wire. EMA accepts marketing application for somatrogon to treat pediatric patients with growth hormone deficiency. Business Wire. (2021) Accessed 2021 Feb 26. Available from: https://www.businesswire.com/news/home/20210226005102/en/
   Google Scholar
• Specialist Pharmacy Service. Somatrogon. (2017). [cited 2023 Apr 22]. Available from: https://www.sps.nhs.uk/medicines/somatrogon/
   Google Scholar
• Kaplan Medical Center R, Israel, Zadik Z, Zelinska N, et al. Results from an open-label extension of the Phase 2 dose finding study of Once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency (GHD). J Endocr Soc. 2022;5(Supplement_1):A684–5.
   Google Scholar
• Allen DB, Merchant N, Miller BS, et al. Evolution and future of growth plate therapeutics. Horm Res Paediatr. 2021;94(9–10):319–332. doi: 10.1159/000520812
   PubMed Web of Science ®Google Scholar
• Raman S, Grimberg A, Waguespack SG, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy–A report from the Pediatric Endocrine Society drug and Therapeutics Committee. J Clin Endocrinol Metab. 2015;100(6):2192–203. doi: 10.1210/jc.2015-1002
   PubMed Web of Science ®Google Scholar
• Djambas Khayat C. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. J Blood Med. 2016;7:275–282. doi: 10.2147/JBM.S84597
   PubMed Web of Science ®Google Scholar
• Tahrani A, Jose B, Piya MK, et al. Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer Adherence. 2010;4:313–24. doi: 10.2147/PPA.S7494
   PubMed Web of Science ®Google Scholar
• Li A, Goodfriend C, Sokol J, et al. Patterns and predictors of emicizumab adherence in people with hemophilia. Blood. 2019;134(Supplement_1):2178. doi: 10.1182/blood-2019-128083
   Web of Science ®Google Scholar
• Qiao Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diab Metab Syndr Obes. 2016;9:201–5. doi: 10.2147/DMSO.S99732
   PubMed Web of Science ®Google Scholar
• Loftus J, Miller BS, Parzynski CS, et al. Association of daily growth hormone injection adherence and height among children with growth hormone deficiency. Endocr Pract. 2022;28(6):565–571. doi: 10.1016/j.eprac.2022.02.013
   PubMed Web of Science ®Google Scholar
• Bouhours-Nouet NTC, Teinturier C. Long-acting recombinant human growth hormone in the treatment of pediatric growth hormone deficiency, how far have we got? Arch Pediatr. 2022;28(8):/28/814–/28/820. doi: 10.1016/S0929-693X(22)00038-0
   Web of Science ®Google Scholar
• Miller BS, Rosenfeld RG. Monitoring rhGH Safety: rhGH Registries, SAGhE and Future Needs. Pediatr Endocrinol Rev. 2018;16(Suppl 1):150–161. doi: 10.17458/per.vol16.2018.mr.monitoringrhghsafety
   PubMedGoogle Scholar
• Savendahl L, Cooke R, Tidblad A, et al. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol. 2020;8(8):683–692. doi: 10.1016/S2213-8587(20)30163-7
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Albertsson-Wikland K, et al. Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr. 2015;84(3):172–183. doi: 10.1159/000435856
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Beckers D, et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab. 2017;102(5):1661–1672. doi: 10.1210/jc.2016-2046
   PubMed Web of Science ®Google Scholar
• Geffner ME, Ibanez L, Maniatis A, et al. Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): a Multi-Country, Non-Interventional, Prospective, Cohort Study of Patients Receiving Human Growth Hormone Treatments Under Routine Clinical Care. ENDO; Atlanta (GA) USA; 2022.
   Google Scholar
• Miller B, Savendahl L, Hickman K, et al. A Long-Acting Growth Hormone Module For Paediatric Growth Hormone Deficiency In The Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions – The GloBE-Reg LAGH Study. ESPE; Rome Italy; 2022.
   Google Scholar